Grant: Engage Grants Program
University of Ottawa
$25,000.00
Improving the binding specificity and affinity of prenyltransferase enzymes using computational protein design********
FY 2018-19
Summary
Cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) are becoming increasingly important pharmaceuticals for the treatment of a variety of human diseases such as chronic pain, epilepsy, and Parkinson's disease. Currently, these compounds are extracted from the plant Cannabis sativa, which produces hundreds of active biological compounds in addition to THC and CBD. The presence of these additional compounds makes it difficult to standardize C. sativa extracts to be used as medicine. To address this issue, Hyasynth Bio is developing an alternative production method for high purity cannabinoids that is based on yeast fermentation. This method relies on a heterologous biosynthetic pathway including non-plant prenyltransferases, which catalyze the transfer of a C5 (dimethylallyl), C10 (geranyl) or C15 (farnesyl) prenyl group derived from the corresponding isoprenyl diphosphate metabolites onto a variety of aromatic acceptors. However, these prenyltransferases display broad substrate and regio-specificity, making them able to react with many undesired aromatic yeast metabolites or prenylate desired ones at incorrect positions, which lowers the overall efficiency of the pathway. To enhance the efficiency of the fermentation process and thereby the value of these enzymes to the pharmaceutical and recreational cannabis markets, we will use computational protein design to engineer prenyltransferase variants displaying narrow specificity and enhanced binding affinity to their target substrates. These engineered prenyltransferases will directly integrate into Hyasynth Bio's metabolic engineering and fermentation process pipelines, thereby providing the company with a competitive edge in the cannabis industry and directly contributing to the development of the Canadian bio-economy.*
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
537415-2018
Name nom
Chica, Roberto
Department département
Chemistry
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5404
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Enzymes
Research subject fr
Enzymes
Partie
1
Nb partie
1
Application title
Improving the binding specificity and affinity of prenyltransferase enzymes using computational protein design********
Keyword
NSERC
Application summary
Cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) are becoming increasingly important pharmaceuticals for the treatment of a variety of human diseases such as chronic pain, epilepsy, and Parkinson's disease. Currently, these compounds are extracted from the plant Cannabis sativa, which produces hundreds of active biological compounds in addition to THC and CBD. The presence of these additional compounds makes it difficult to standardize C. sativa extracts to be used as medicine. To address this issue, Hyasynth Bio is developing an alternative production method for high purity cannabinoids that is based on yeast fermentation. This method relies on a heterologous biosynthetic pathway including non-plant prenyltransferases, which catalyze the transfer of a C5 (dimethylallyl), C10 (geranyl) or C15 (farnesyl) prenyl group derived from the corresponding isoprenyl diphosphate metabolites onto a variety of aromatic acceptors. However, these prenyltransferases display broad substrate and regio-specificity, making them able to react with many undesired aromatic yeast metabolites or prenylate desired ones at incorrect positions, which lowers the overall efficiency of the pathway. To enhance the efficiency of the fermentation process and thereby the value of these enzymes to the pharmaceutical and recreational cannabis markets, we will use computational protein design to engineer prenyltransferase variants displaying narrow specificity and enhanced binding affinity to their target substrates. These engineered prenyltransferases will directly integrate into Hyasynth Bio's metabolic engineering and fermentation process pipelines, thereby providing the company with a competitive edge in the cannabis industry and directly contributing to the development of the Canadian bio-economy.*